**Background**

The modulation of G protein-coupled receptors (GPCRs) is a fundamental strategy in treating a wide array of physiological disorders. Among these, the H1 histamine receptor and muscarinic acetylcholine receptors (mAChRs) play critical roles in regulating allergic responses, nausea, and central nervous system arousal. Furthermore, serotonin receptors, specifically the 5-HT2A and 5-HT2C subtypes, are essential targets for understanding hallucinogenic effects and mood regulation. Beyond its classical pharmacological applications, recent research has highlighted the potential of certain phenothiazine derivatives to influence adipogenesis and ectopic fat formation, opening new avenues for metabolic research. In this context, we will introduce a versatile phenothiazine derivative – Promethazine.

**Definition**

Promethazine is an orally active phenothiazine derivative that acts as a potent H1 receptor antagonist and mAChR antagonist, while also exhibiting affinity for 5-HT2A and 5-HT2C receptors.

**In Vitro and In Vivo Studies**

According to the Promethazine description, this compound possesses a variety of antihistaminic, sedative, antiemetic, and anticholinergic properties. Promethazine in vitro studies have demonstrated its impact on metabolic processes; specifically, concentrations of 1.25-10 μM over 3 days inhibit adipocyte formation in a dose-dependent manner. Furthermore, treatment with 10 μM for 0-12 days decreases the expression of peroxisome proliferator activated receptor γ (PPARG) and reduces the phosphorylation level of CREB in PDGFRα+ cells. Regarding cellular toxicity, Promethazine biological activity in L929 lung fibroblast cells shows cytotoxic effects at concentrations exceeding 100 μM within 1-24 hours. Additionally, in SARS-CoV-2 infected Vero E6 cells, Promethazine exhibits IC50 values of 9.21 μM (at MOI 0.004) and 10.44 μM (at MOI 0.01), with CC50 values > 42.59 μM.

Promethazine In Vivo research has further explored its therapeutic potential. In a mouse achilles tendon rupture model, administration of 0.05-0.1 mg/mL via oral gavage for 4 weeks showed an inhibitory effect on the formation of ectopic fat cells in skeletal muscle. In other studies, doses of 2.4-9.6 mg/kg (p.o.) in adult castrate male rats were found to have no effect on the development of femoral osteoporosis, although they retarded normal femoral expansion. In conclusion, Promethazine is a multi-target antagonist with significant applications in antihistamine, antiemetic, and metabolic research.

Keywords

Promethazine, 58-33-3, Histamine Receptor, mAChR, Adrenergic Receptor, Muscarinic acetylcholine receptor, Beta Receptor, antihistaminic (H1), sedative, antiemetic, anticholinergic, antimotion sickness, H1 receptor antagonist, Inhibitor, inhibitor

References

[1] Fiorella D, et al. The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. I: Antagonist correlation analysis. Psychopharmacology (Berl). 1995 Oct;121(3):347-56.
[2] Kasai T, et al. Promethazine Hydrochloride Inhibits Ectopic Fat Cell Formation in Skeletal Muscle. Am J Pathol. 2017 Dec;187(12):2627-2634.
[3] McDonough JA, et al. Microcapsule-gel formulation of promethazine HCl for controlled nasal delivery: a motion sickness medication. J Microencapsul. 2007 Mar;24(2):109-16.
[4] Wink CS, et al. Effects of promethazine HCl on osteoporotic femora of adult castrated male rats. Acta Anat (Basel).

**Background**

Estrogen receptors play a critical role in the regulation of various physiological processes, including the maintenance of the female reproductive system and the modulation of bone density. Dysregulation of estrogen signaling is often associated with menstrual disorders and menopausal symptoms, making the estrogen receptor a primary target for hormone replacement therapy and the study of endocrine-related pathologies. In the context of oncology, the role of estrogen in promoting the growth of certain breast cancer subtypes further emphasizes the need for precise pharmacological tools to study these pathways. Therefore, we will introduce a synthetic estrogen proagent – Mestranol.

**Definition**

Mestranol is an inactive proagent that acts as an estrogen receptor agonist upon its conversion to the biologically active ethinyl estradiol (EE). According to the Mestranol technical information, it is a low potency synthetic estrogen with a molecular weight of 310.43 and a specific Mestranol formula of C21H26O2.

**In Vitro Studies**

Mestranol is utilized as a click chemistry reagent containing an Alkyne group, allowing it to undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Regarding Mestranol biological activity, in vitro studies have demonstrated that it is significantly more stable than 17β-Estradiol in hepatoma cell cultures. Specifically, Mestranol (10 μM; 6 days) stimulates the growth of ER-positive MCF-7 WS8 cells up to 250% of control levels, an effect that can be partially reversed by tamoxifen. Conversely, in Hep G2 hepatoma cells, Mestranol (10 μM; 6 days) inhibits the growth of Hep 3B cells by 40% compared to control cells; this inhibitory effect is additive when combined with tamoxifen. Additionally, the antiproliferative activity of Mestranol against human MCF7 cells has been assessed, yielding an IC50 value of 40 nM when incubated for 6 days via SRB assay. In vivo, Mestranol can be combined with a progestin for the research of menstrual disorders or menopausal hormones. In conclusion, Mestranol is a versatile synthetic estrogen proagent and click chemistry tool suitable for research in hormone-dependent disorders and Mestranol Cancer studies.

Keywords

Mestranol, 72-33-3, Estrogen Receptor/ERR, prodrug, ethinyl estradiol, menopausal hormone, menstrual disorder, MCF-7, Hep G2, hepatoma, Inhibitor, inhibitor, inhibit

References

[1] H Kappus, et al. Affinity of ethynyl-estradiol and mestranol for the uterine estrogen receptor and for the microsomal mixed function oxidase of the liver. J Steroid Biochem. 1973 Mar;4(2):121-8.
[2] J W Goldzieher, et al. Pharmacokinetics of ethinyl estradiol and mestranol. Am J Obstet Gynecol. 1990 Dec;163(6 Pt 2):2114-9.
[3] S Y Jiang, et al. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol. 1995 Dec;23(6):712-9.

**Background**

Bronchial diseases, such as asthma and chronic obstructive pulmonary disease (COPD), are characterized by airway inflammation and constriction, which significantly impair respiratory function and quality of life. A key mechanism in the regulation of airway tone is the activation of muscarinic receptors by acetylcholine, which leads to bronchoconstriction. Therefore, targeting these receptors with antagonists is a critical strategy for achieving bronchodilation and protecting the pulmonary system. In this context, we will introduce a muscarinic receptor antagonist – Glycopyrrolate.

**Definition**

Glycopyrrolate (Glycopyrronium bromide) is a quaternary ammonium derivative that functions as a muscarinic receptor antagonist. According to the Glycopyrrolate description, this compound is utilized primarily in the research of bronchial diseases due to its bronchoprotective effects and its ability to influence blood pressure.

**In Vitro and In Vivo Studies**

The Glycopyrrolate biological activity has been demonstrated across various experimental models. In terms of Glycopyrrolate In Vitro studies, the application of Glycopyrrolate (1-10 nM for 30 min) has shown a protective effect on both large and small airways in guinea pig lung slices. These findings suggest its potential for mitigating intrapulmonary airway constriction.

Regarding Glycopyrrolate In Vivo research, the compound has been evaluated for its cardiovascular effects in anesthetized dogs. Administration of Glycopyrrolate (0.005-0.01 mg/kg via intravenous injection, as a single dose or a second dose if heart rate is below 70 beats/min) produces a beneficial effect on blood pressure. Specifically, dosages of 0.005 mg/kg and 0.01 mg/kg resulted in a significant increase in heart rate (HR), as well as significant increases in systolic, diastolic, and mean blood pressure above baseline values. For researchers seeking detailed Glycopyrrolate technical information, these results highlight the compound’s systemic physiological impact. In conclusion, Glycopyrrolate is a potent muscarinic receptor antagonist that provides significant bronchoprotection and cardiovascular modulation.

Keywords

Glycopyrrolate, 596-51-0, Glycopyrronium, mAChR, Muscarinic acetylcholine receptor, Chronic obstructive pulmonary disease, Anesthetized dogs, Anticholinergic, Inhibitor, inhibitor, inhibit

References

[1] Maarsingh H, et al. Effects of (a Combination of) the Beta2-Adrenoceptor Agonist Indacaterol and the Muscarinic Receptor Antagonist Glycopyrrolate on Intrapulmonary Airway Constriction [J]. Cells, 2021, 10(5): 1237.
[2] Dyson D H, et al. Dose effect and benefits of glycopyrrolate in the treatment of bradycardia in anesthetized dogs [J]. The Canadian Veterinary Journal, 1999, 40(5): 327.
[3] Hansel T T, Neighbour H, Erin E M, et al. Glycopyrrolate causes prolonged bronchoprotection and bronchodilatation in patients with asthma [J]. Chest, 2005, 128(4): 1974-1979.

**Background**

Protein arginine methyltransferases (PRMTs) play a critical role in regulating gene expression and signal transduction through the methylation of arginine residues on various proteins. Among these, PRMT5 is a key enzyme involved in the methylation of histone H4R3, which is often dysregulated in various malignancies and inflammatory conditions. Specifically, PRMT5 activity is frequently hijacked to drive the initiation and maintenance of B-cell transformation, making it a promising target for cancer therapy. Furthermore, PRMT5 inhibition has shown potential in suppressing aberrant T cell responses in autoimmune diseases. In this context, we will introduce a potent and selective PRMT5 inhibitor – CMP-5.

**Definition**

CMP-5 is a potent, specific, and selective PRMT5 inhibitor that selectively blocks S2Me-H4R3 by inhibiting PRMT5 methyltransferase activity on histone preparations. According to the CMP-5 description, it displays no activity against PRMT1, PRMT4, and PRMT7 enzymes.

**In Vitro Studies**

The CMP-5 biological activity has been extensively evaluated in various cell models. In vitro studies demonstrate that CMP-5 (0-100 μM; 24-72 hours) is selectively toxic to lymphoma cells while showing limited toxicity to normal resting B lymphocytes, even after prolonged incubation. Furthermore, CMP-5 prevents Epstein-Barr virus (EBV)-driven B-lymphocyte transformation without affecting normal B cells. In 60A cells, treatment with CMP-5 (40 μM; 24 hours) significantly decreases the expression of p-BTK and pY(416) SRC compared to DMSO-treated groups. Regarding immune response modulation, CMP-5 (0-40 μM; 24 hours) preferentially suppresses the proliferation of human Th1 cells over Th2 cells, with IC50 values of 26.9 μM and 31.6 μM, respectively. Additionally, CMP-5 (25 μM; 24 hours) alone inhibits mouse Th1 cell proliferation by 91%, although this effect can be partially reversed by the addition of IL-2 in a dose-dependent manner. In conclusion, CMP-5 is a highly selective PRMT5 inhibitor that holds significant potential for research in CMP-5 cancer and inflammatory T cell response studies.

Keywords

CMP-5, 880813-42-3, CMP5, CMP 5, Histone Methyltransferase, lymphoma, cells, Th1, Th2, 60A, EBV, PRMT5, B-lymphocyte, S2Me-H4R3, Inhibitor, inhibitor, inhibit

References

[1] Alinari L, et al. Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation.Blood. 2015 Apr 16;125(16):2530-43.
[2] Webb LM, et al. PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis. J Immunol. 2017 Feb 15;198(4):1439-1451.

**Background**

Nucleoside transport and metabolism are critical processes for maintaining cellular homeostasis and regulating the availability of precursors for nucleic acid synthesis. Among the enzymes involved in these pathways, 5′-methylthioadenosine phosphorylase (MTAP) plays a significant role in the salvage pathway of adenine and the metabolism of sulfur-containing compounds. Understanding the transport mechanisms of nucleosides is essential for developing targeted drug delivery systems and studying metabolic disorders. In cells lacking MTAP, the use of non-metabolizable substrates becomes a vital tool for conducting precise nucleoside transport assays. In this context, we will introduce a specialized substrate for these studies – 5′-Deoxyadenosine.

**Definition**

5′-Deoxyadenosine is a deoxyadenosine analog that serves as a substrate for 5′-methylthioadenosine phosphorylase. According to the 5′-Deoxyadenosine description, it functions as a non-metabolizable substrate specifically in cells that lack the expression of 5′-methylthioadenosine phosphorylase.

**In Vitro Studies**

The 5′-Deoxyadenosine biological activity has been extensively evaluated across various cell lines to determine its metabolic stability and enzymatic affinity. In vitro studies demonstrate that 5′-Deoxyadenosine serves as a potent substrate for 5′-methylthioadenosine phosphorylase in plant cells and Sarcoma 180 cells. Conversely, when tested in L1210 mouse leukemia cells, the compound is not significantly phosphorylated, deaminated, or metabolized by any other known cellular pathways. This metabolic stability makes it an ideal tool for researchers seeking to isolate transport kinetics from metabolic interference. For those requiring specific 5′-Deoxyadenosine technical information, it is characterized by a molecular weight of 251.25 and a chemical formula of C10H13N5O3. In conclusion, 5′-Deoxyadenosine is a valuable biochemical tool for the study of nucleoside transport and MTAP enzymatic activity.

Keywords

5′-Deoxyadenosine, 4754-39-6, Nucleoside Antimetabolite/Analog, Phosphorylase, mammalian cells, adenine phosphoribosyl transferase, 2′-deoxyadenosine, 5-deoxyribose-1-phosphate, 3′-deoxyadenosine, CHO cells, 5′-methylthioadenosine phosphorylase, hypoxanthine, adenine, leukemia cells, Inhibitor, inhibitor, inhibit

References

[1] Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.

**Background**

Anxiety and depression are prevalent psychiatric disorders that significantly impact global health and quality of life. These conditions are often associated with imbalances in neurotransmitter systems, particularly the serotonergic system. The 5-HT1A receptor, a subtype of the serotonin receptor, plays a critical role in modulating mood, anxiety, and stress responses. Targeting this receptor has become a primary strategy for developing pharmacological interventions to alleviate psychiatric symptoms and associated systemic inflammation. In this context, we will introduce a 5-HT1A receptor agonist – Buspirone.

**Definition**

Buspirone is a 5-HT1A receptor agonist with the molecular formula C21H32ClN5O2 and a molecular weight of 421.96.

**In Vitro and In Vivo Studies**

The Buspirone biological activity has been extensively studied across various models to understand its therapeutic and toxicological profiles. In vitro studies using human blood lymphocytes demonstrated that Buspirone (0-400 μg/mL; 6 hours) exerts a cytotoxic effect, decreasing cell viability in a dose-dependent manner. Furthermore, Buspirone in vitro (0-180 μg/mL; 0-3 hours) was found to induce the formation of reactive oxygen species (ROS), cause mitochondrial membrane potential (MMP) collapse, trigger lipid peroxidation, lead to lysosomal damage, and elevate glutathione disulfide (GSSG) levels.

Regarding Buspirone In Vivo, research using male C57BL/6N mice showed that administration of Buspirone (1-5 mg/kg; i.p. and i.g.; for 5 days) significantly reduces anxiety- and depression-like behaviors. These effects are accompanied by a reduction in TNF-α expression and a decrease in the NF-κB+/Iba1+ cell population in the hippocampus, as well as reduced myeloperoxidase activity and NF-κB+/CD11c+ cell populations in the colon. Additionally, the treatment restored IS-shifted β-diversity in the gut microbiota and reduced the IS- or EC-induced Proteobacteria population in the gut. For researchers seeking detailed Buspirone technical information, these findings highlight the drug’s potential to modulate the gut-brain axis. In conclusion, Buspirone is a 5-HT1A receptor agonist that effectively alleviates anxiety and depression while modulating gut microbiota and neuroinflammation.

Keywords

Buspirone, 33386-08-2, 5-HT Receptor, Reactive Oxygen Species (ROS), Serotonin Receptor, 5-hydroxytryptamine Receptor, 5-HT1A receptor, anxiety, depression, Inhibitor, inhibitor, inhibit

References

[1] Salimi A, et, al. Analysis of Toxicity Effects of Buspirone, Cetirizine and Olanzapine on Human Blood Lymphocytes: in Vitro Model. Curr Clin Pharmacol. 2018;13(2):120-127.
[2] Kim JK, et, al. Buspirone alleviates anxiety, depression, and colitis; and modulates gut microbiota in mice. Sci Rep. 2021 Mar 17;11(1):6094.

Periodontitis is a chronic inflammatory condition characterized by progressive destruction of the alveolar bone and periodontal ligament, leading to tooth mobility and loss. Despite advances in mechanical debridement, conventional treatments often fail to achieve sustained therapeutic outcomes due to inadequate drug delivery kinetics. Localized antibiotic therapy has become an essential adjunct, with minocycline hydrochloride (MINO) emerging as a preferred agent owing to its potent antibacterial activity and ability to stimulate osteoblast proliferation and bone formation. However, clinical application is limited by rapid initial release, short duration of action, and potential cytotoxicity at high concentrations. To overcome these limitations, this study developed an electrosprayed MINO-loaded microsphere/sucrose acetate isobutyrate (SAIB) hybrid depot designed for prolonged, controlled release with enhanced biocompatibility and regenerative capacity.

Microspheres were fabricated using PLGA and PEG via electrospray technology, yielding spherical particles with an average diameter of 5.3 µm and low coefficient of variation (CV < 10%), indicating excellent monodispersity. Drug loading was adjusted at 10%, 12%, and 14% (w/w), with encapsulation efficiencies decreasing from 65.57% to 48.04% as loading increased—attributed to polymer saturation and surface drug accumulation. Scanning electron microscopy revealed slightly rough surfaces, likely due to incomplete solvent evaporation during electrospraying, which may enhance cell adhesion and tissue integration. Contact angle measurements confirmed increasing hydrophilicity with higher MINO content, suggesting improved surface wettability and faster hydration upon injection. When incorporated into SAIB, the hybrid depots exhibited a significant reduction in burst release—from over 70% to less than 5% within the first 24 hours. In vitro release profiles demonstrated sustained delivery lasting up to 77 days, with a consistent release rate exceeding 0.38% per day after day 10. The release mechanism followed a diffusion-controlled pattern, as indicated by the Ritger-Peppas model with n-values between 0.4 and 0.5. Degradation studies showed that all microspheres underwent biphasic degradation: an initial rapid phase followed by a slower, steady-state erosion, consistent with hydrolytic breakdown of PLGA. No significant differences in degradation rates were observed across different drug loadings, confirming that MINO concentration did not influence polymer degradation kinetics. Porosity analysis revealed a rapid increase in pore formation during the first 15 days, correlating with accelerated drug release. After day 15, porosity growth slowed, aligning with the sustained release phase. This dynamic porosity development is driven by water uptake and solvent diffusion upon injection into physiological environments. Cytotoxicity assays using CCK-8 demonstrated that the 12% drug-loaded formulation (M2-SAIB) maximized osteoblast proliferation, while higher concentrations induced mild inhibition. Based on this result, M2-SAIB was selected for in vivo evaluation. In a ligature-induced periodontitis rat model, the MINO-microsphere/SAIB depot significantly outperformed control and non-drug-loaded SAIB groups.5-tert-Butylisophthalic acid medchemexpress Micro-computed tomography (micro-CT) analysis revealed marked increases in alveolar bone height and bone volume/tissue volume (BV/TV) ratios at both 3 and 6 weeks post-treatment.Tetrahydrofuran-2,5-dicarboxylic acid web Histological examination (H&E staining) showed reduced inflammation, reattachment of junctional epithelium, and substantial new bone deposition.PMID:34487151 Immunohistochemistry confirmed downregulation of RANKL and upregulation of OPG, indicating suppression of osteoclastogenesis and promotion of bone homeostasis.

These findings demonstrate that the electrosprayed MINO-microsphere/SAIB hybrid depot offers a highly effective solution for long-term periodontal therapy. By combining the precision of electrospray fabrication with the tunable release properties of SAIB, the system achieves prolonged, controlled delivery of MINO, minimizing local toxicity while maximizing antibacterial and osteogenic effects. Its injectable nature allows easy placement in periodontal pockets, reducing treatment frequency and improving patient compliance. This innovative approach holds strong promise for clinical translation, offering a comprehensive strategy that simultaneously treats infection and promotes tissue regeneration in periodontitis management.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com

Protein vesicles have emerged as a transformative platform in nanomedicine, offering a unique combination of biocompatibility, structural stability, and genetic programmability. In this study, we present a highly advanced, genetically engineered protein vesicle system designed for the precision co-delivery of therapeutic proteins and small molecule drugs. The platform is built upon recombinant fusion proteins that self-assemble into stable, tunable vesicles with controlled size, encapsulation efficiency, and stimuli-responsive release profiles—key attributes for effective intracellular delivery.

The core architecture consists of two modular components: ZR-ELP, a hydrophobic elastin-like polypeptide (ELP) fused to an arginine-rich leucine zipper motif, and mCherry-ZE, a hydrophilic globular fluorescent protein linked to a glutamic acid-rich leucine zipper. These domains form high-affinity heterodimers via coiled-coil interactions, driving spontaneous assembly into amphiphilic “globule-zipper-ELP” structures in aqueous solution. Upon heating above the lower critical solution temperature (Tt), the ELP undergoes a reversible phase transition from soluble to insoluble, leading to the formation of hollow, spherical vesicles. This process is thermally triggered and fully reversible, but without stabilization, the vesicles disassemble under physiological conditions due to dilution or salt changes.Phospho-Tau Antibody supplier

To address this instability, we incorporated para-azido phenylalanine (pAzF), a photoreactive unnatural amino acid, into the ELP domain through genetic code expansion in engineered Escherichia coli. UV irradiation induces photocrosslinking between adjacent pAzF residues, forming covalent bonds that lock the vesicle structure while preserving the native conformation of embedded functional proteins. This strategy avoids nonspecific crosslinking and eliminates cytotoxic chemical reagents. Circular dichroism (CD) analysis confirmed no disruption of secondary structure in mCherry post-crosslinking, ensuring retention of fluorescence and bioactivity.

A defining feature of this system is its tunability. By varying the ratio of ZR-ELP to pZR-ELP during assembly, we can precisely control the degree of crosslinking and thus regulate vesicle swelling and mechanical stability. Higher pAzF content leads to more rigid, less swollen vesicles with slower release kinetics, while reduced crosslink density allows for greater expansion and faster cargo release. Additionally, increasing ionic strength during assembly—up to 2 M NaCl—induces charge screening and salting-out effects, promoting a more compact ELP conformation and yielding smaller vesicles (~94 nm). This enables nanoscale size control, critical for enhanced tumor penetration via the enhanced permeability and retention (EPR) effect.

We evaluated the system’s ability to co-encapsulate doxorubicin hydrochloride (DOX), a water-soluble anticancer drug, and sfGFP-ZE, a model therapeutic protein. DOX was loaded during thermally triggered self-assembly at 25°C, achieving encapsulation efficiencies of up to 82.5% under high-salt conditions. The vesicles effectively retained DOX during dialysis against PBS (0.137 M NaCl), indicating low membrane permeability. Upon exposure to physiological salt levels, gradual release occurred over 30 hours, with approximately 89% of DOX released—demonstrating a sustained, environment-sensitive profile driven by ELP rehydration and chain expansion.

Cellular uptake studies using HeLa cells confirmed efficient internalization via endocytosis. Confocal microscopy revealed colocalization of red mCherry fluorescence in the vesicle membrane and green sfGFP signal in the cytoplasm, confirming successful delivery of both cargos.Penicillin-Streptomycin web After 16 hours, significant accumulation of sfGFP was observed in the nucleus, indicating intact functionality and intracellular activity.PMID:34303762 Flow cytometry validated these results, showing robust dual delivery with minimal leakage.

Notably, empty vesicles exhibited no cytotoxicity at concentrations up to 9 µM, underscoring excellent biocompatibility. Furthermore, the modular design allows easy replacement of mCherry or sfGFP with other functional proteins—such as enzymes, cytokines, or targeting ligands—by simply swapping the ZE-fused protein. This enables on-demand surface display of therapeutic agents, paving the way for personalized, multifunctional nanocarriers.

In summary, this genetically engineered protein vesicle system offers unprecedented control over size, stability, release kinetics, and cargo versatility. Its ability to simultaneously deliver small molecules and functional proteins makes it ideal for combination therapies, including those involving synergistic drugs and biologics. With further development for pH-, enzyme-, or light-triggered release, these vesicles hold strong promise as intelligent nanomedicines capable of minimizing off-target effects while maximizing therapeutic impact in vivo.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com